share_log

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.7%),The Tiger Cub Trust(28.6%)

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.7%),The Tiger Cub Trust(28.6%)

Mangoceuticals | SC 13D/A:超過5%持股股東披露文件(修正)-Jacob D. Cohen(34.7%),The Tiger Cub Trust(28.6%)
美股SEC公告 ·  06/05 17:18

Moomoo AI 已提取核心訊息

On June 3, 2024, Mangoceuticals, Inc. experienced a significant event involving its stock ownership. Jacob D. Cohen, the company's CEO and Chairman, received an issuance of 800,000 fully-vested shares of common stock as a bonus for the year 2024. This decision was approved by the Board of Directors with the recommendation of the Compensation Committee. The Schedule 13D/A filing with the SEC, which is an amendment to the previous filings, reflects this change. As a result, Jacob D. Cohen now beneficially owns 10,575,000 shares, representing 34.7% of the company's common stock. Additionally, The Tiger Cub Trust, also a reporting person, holds 8,275,000 shares, which accounts for 28.6% of the common stock. These ownership percentages are based on 28,943,143 shares of common stock outstanding as of June 5, 2024. The filing confirms that no other person has the right to receive dividends or proceeds from the sale of the securities owned by the reporting persons.
On June 3, 2024, Mangoceuticals, Inc. experienced a significant event involving its stock ownership. Jacob D. Cohen, the company's CEO and Chairman, received an issuance of 800,000 fully-vested shares of common stock as a bonus for the year 2024. This decision was approved by the Board of Directors with the recommendation of the Compensation Committee. The Schedule 13D/A filing with the SEC, which is an amendment to the previous filings, reflects this change. As a result, Jacob D. Cohen now beneficially owns 10,575,000 shares, representing 34.7% of the company's common stock. Additionally, The Tiger Cub Trust, also a reporting person, holds 8,275,000 shares, which accounts for 28.6% of the common stock. These ownership percentages are based on 28,943,143 shares of common stock outstanding as of June 5, 2024. The filing confirms that no other person has the right to receive dividends or proceeds from the sale of the securities owned by the reporting persons.
2024年6月3日,Mangoceuticals公司發生了一件涉及其股權的重大事件。公司的CEO和董事長Jacob D. Cohen在2024年的獎金中獲得了80萬股全數投資股票的派發。這個決定經董事會批准,並獲得薪酬委員會的推薦。向美國證券交易委員會提交的13D/A表格,是對先前提交的申報的修改,並反映了這一變化。因此,Jacob D. Cohen現在擁有1,057.5萬股股票,佔公司普通股的34.7%。此外,同樣是申報人的Tiger Cub Trust持有827.5萬股股票,佔普通股28.6%。這些所有權百分比是基於截至2024年6月5日的2894,3143股普通股。該申報確認,沒有其他人有權從申報人擁有的證券中獲得分紅或出售收益。
2024年6月3日,Mangoceuticals公司發生了一件涉及其股權的重大事件。公司的CEO和董事長Jacob D. Cohen在2024年的獎金中獲得了80萬股全數投資股票的派發。這個決定經董事會批准,並獲得薪酬委員會的推薦。向美國證券交易委員會提交的13D/A表格,是對先前提交的申報的修改,並反映了這一變化。因此,Jacob D. Cohen現在擁有1,057.5萬股股票,佔公司普通股的34.7%。此外,同樣是申報人的Tiger Cub Trust持有827.5萬股股票,佔普通股28.6%。這些所有權百分比是基於截至2024年6月5日的2894,3143股普通股。該申報確認,沒有其他人有權從申報人擁有的證券中獲得分紅或出售收益。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息